A regulatory alert from the law firm Kelley Drye & Warren LLP confirms that the U.S. Food and Drug Administration has shifted from framework-setting to active enforcement under the Modernization of Cosmetics Regulation Act (MoCRA), layering additional regulatory efforts on top of the statute's mandates.

The firm published the alert under the headline "FDA Signals Increased Cosmetics Oversight through MoCRA Implementation and Other Regulatory Efforts", framing FDA's posture as multi-channel and ongoing rather than driven by a single rule or inspection campaign.

What does the Kelley Drye alert signal for manufacturers?

The legal alert positions MoCRA implementation as the backbone of the agency's expanded oversight. The "Other Regulatory Efforts" component signals that FDA is layering additional actions beyond MoCRA itself, raising the compliance bar for the industry as a whole.

Kelley Drye's consumer products practice has tracked FDA cosmetics enforcement closely since MoCRA's enactment in late 2022. The firm functions as a bellwether legal observer for the sector, so its framing reaches compliance leads at every major brand owner and contract manufacturer.

What does this mean for product development and compliance workload?

Compliance teams face concentrated pressure at three operational pinch points:

• Facility registration and product listing: every cosmetic product placed on the U.S. market requires a current FDA listing. Formula or supplier changes trigger updates.
• Safety substantiation: each finished product requires documented support for safety, a task that pushes documentation burden toward formulators and toxicology reviewers.
• Adverse event reporting: manufacturers, distributors and brand owners face mandatory timelines for serious adverse events, requiring functional intake and routing systems.

These obligations converge during FDA inspections, where agency staff now expect records to be retrievable on demand rather than supplied reactively.

How does this affect procurement and supply chains?

Procurement teams sourcing ingredients and packaging should expect upstream questions to reach suppliers. FDA inquiries trace back through certificates of analysis, raw material specifications, allergen statements and country-of-origin documentation.

Contract manufacturers face parallel exposure when filling private-label orders on behalf of brand owners, with liability tracking back to the entity listed on the FDA product registration. Brands importing finished cosmetics into the U.S. must validate that their overseas partners are registered, listed and operating under practices compatible with FDA's expectations.

What enforcement vectors should compliance teams prepare for next?

The "other regulatory efforts" referenced in the alert headline sit across multiple agency tracks. Watch for finalized guidance documents and implementing rules tied to MoCRA's substantiation, fragrance disclosure, color additive and PFAS touchpoints as the leading signal of where the next enforcement wave will land.

What is the next data point to watch?

The Kelley Drye alert directs regulated entities to forthcoming FDA guidance documents and inspection protocols as the next operational data points. Brand owners without current compliance documentation should treat the alert as a planning trigger ahead of inspection cycles scheduled through 2025 and 2026.

The agency's enforcement capacity is also a variable: budget appropriations, staffing levels and finalized guidance shape whether MoCRA obligations translate into broader enforcement or remain focused on narrower product categories. Forthcoming Federal Register notices and any cosponsored regulatory actions touching allergens, PFAS or color additives will be the leading indicators of where FDA lands next.